1. Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients
- Author
-
William E. Boden, Chin Ying, Drew Pierce, Kulpreet Barn, Oleh Pankewycz, and Mark R. Laftavi
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,Vascular disease ,Cholesterol ,Odds ratio ,medicine.disease ,chemistry.chemical_compound ,High-density lipoprotein ,chemistry ,Internal medicine ,Diabetes mellitus ,Cardiology ,Medicine ,lipids (amino acids, peptides, and proteins) ,Risk factor ,business ,Kidney transplantation - Abstract
Long-term kidney transplant graft and patient survival is often limited by cardiovascular (CV) disease. Risk factors for CV disease such as diabetes, hypertension and elevated low-density lipoprotein levels are well documented; however, the impact of low levels of high-density lipoprotein (HDL) has not been defined. We performed a retrospective chart review of 324 consecutive renal transplant recipients from 2001 to 2007 to correlate baseline HDL levels with major adverse cardiovascular events (MACEs) defined as a composite of new onset CV illness, cerebral vascular events and peripheral vascular disease. A total of 92 MACEs occurred over a total of 1913 patient years of follow-up. Low HDL cholesterol levels were noted in 58.3% of patients. Compared with those with normal HDL levels, a greater percentage of patients with low HDL levels had post-transplant MACEs (20% vs. 60% respectively) and experienced an increased rate of all cause mortality. Sixty-two percent of all MACEs occurred in patients with low HDL levels. In the low HDL group, the odds ratio for experiencing a MACE was 1.92. Therefore, HDL cholesterol may provide an important new therapeutic target to prevent vascular morbidity and mortality following renal transplantation.
- Published
- 2009
- Full Text
- View/download PDF